Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
Yuanyuan Xu,1,2,* Xinjin Liu,1,2,* Linghong Guo,1,2 Xian Jiang1,2 1Department of Dermatology, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China; 2Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science...
Saved in:
| Main Authors: | Xu Y, Liu X, Guo L, Jiang X |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-05-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/adverse-events-associated-with-apremilast-and-deucravacitinib-for-psor-peer-reviewed-fulltext-article-CCID |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful treatment by deucravacitinib of psoriasis refractory to apremilast
by: Shigeki Inui, et al.
Published: (2025-06-01) -
Successful Psoriasis Management With Deucravacitinib After Guselkumab‐Associated Eosinophilic Pneumonia
by: Katie K. Lovell, et al.
Published: (2025-06-01) -
Analysis and mining of brodalumab adverse events based on FAERS database
by: Yue Wan, et al.
Published: (2025-05-01) -
Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01) -
A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database
by: Meng Liu, et al.
Published: (2025-08-01)